tetano
Editor, Senior Moderator
Vaccine
. 2023 Jul 31;S0264-410X(23)00892-7.
doi: 10.1016/j.vaccine.2023.07.061. Online ahead of print. An Advax-CpG55.2 adjuvanted recombinant hemagglutinin vaccine provides immunity against H7N9 influenza in adult and neonatal mice
Yoshikazu Honda-Okubo[SUP] 1 [/SUP], Isaac G Sakala[SUP] 1 [/SUP], Greiciely André[SUP] 2 [/SUP], E Bart Tarbet[SUP] 3 [/SUP], Brett L Hurst[SUP] 3 [/SUP], Nikolai Petrovsky[SUP] 4 [/SUP]
Affiliations
There is a major unmet need for strategies to improve the immunogenicity and effectiveness of pandemic influenza vaccines, particularly in poor responder populations such as neonates. Recombinant protein approaches to pandemic influenza offer advantages over more traditional inactivated virus approaches, as they are free of problems such as egg adaptation or need for high level biosecurity containment for manufacture. However, a weakness of recombinant proteins is their low immunogenicity. We asked whether the use of an inulin polysaccharide adjuvant (Advax) alone or combined with a TLR9 agonist (CpG55.2) would enhance the immunogenicity and protection of a recombinant hemagglutinin vaccine against H7N9 influenza (rH7HA), including in neonatal mice. Advax adjuvant induced predominantly IgG1 responses against H7HA, whereas Advax-CpG55.2 adjuvant also induced IgG2a, IgG2b and IgG3 responses, consistent with the TLR9 agonist component inducing a Th1 bias. Advax-CpG55.2 adjuvanted rH7HA induced high serum neutralizing antibody titers in adult mice. In newborns it similarly overcame immune hypo-responsiveness and enhanced serum anti-rH7HA IgG levels in 7-day-old BALB/C and C57BL/6 mice. Immunized adult mice were protected against a lethal H7N9 virus challenge. When formulated with Advax-CpG55.2 adjuvant, greater protection was seen with rH7HA than with inactivated H7 whole virus antigen. Advax-CpG55.2 adjuvanted rH7HA represents a promising influenza vaccine platform for further development.
Keywords: Adjuvant; Advax; Delta inulin; H7N9; Influenza; Pandemic; Vaccine.
. 2023 Jul 31;S0264-410X(23)00892-7.
doi: 10.1016/j.vaccine.2023.07.061. Online ahead of print. An Advax-CpG55.2 adjuvanted recombinant hemagglutinin vaccine provides immunity against H7N9 influenza in adult and neonatal mice
Yoshikazu Honda-Okubo[SUP] 1 [/SUP], Isaac G Sakala[SUP] 1 [/SUP], Greiciely André[SUP] 2 [/SUP], E Bart Tarbet[SUP] 3 [/SUP], Brett L Hurst[SUP] 3 [/SUP], Nikolai Petrovsky[SUP] 4 [/SUP]
Affiliations
- PMID: 37532610
- DOI: 10.1016/j.vaccine.2023.07.061
There is a major unmet need for strategies to improve the immunogenicity and effectiveness of pandemic influenza vaccines, particularly in poor responder populations such as neonates. Recombinant protein approaches to pandemic influenza offer advantages over more traditional inactivated virus approaches, as they are free of problems such as egg adaptation or need for high level biosecurity containment for manufacture. However, a weakness of recombinant proteins is their low immunogenicity. We asked whether the use of an inulin polysaccharide adjuvant (Advax) alone or combined with a TLR9 agonist (CpG55.2) would enhance the immunogenicity and protection of a recombinant hemagglutinin vaccine against H7N9 influenza (rH7HA), including in neonatal mice. Advax adjuvant induced predominantly IgG1 responses against H7HA, whereas Advax-CpG55.2 adjuvant also induced IgG2a, IgG2b and IgG3 responses, consistent with the TLR9 agonist component inducing a Th1 bias. Advax-CpG55.2 adjuvanted rH7HA induced high serum neutralizing antibody titers in adult mice. In newborns it similarly overcame immune hypo-responsiveness and enhanced serum anti-rH7HA IgG levels in 7-day-old BALB/C and C57BL/6 mice. Immunized adult mice were protected against a lethal H7N9 virus challenge. When formulated with Advax-CpG55.2 adjuvant, greater protection was seen with rH7HA than with inactivated H7 whole virus antigen. Advax-CpG55.2 adjuvanted rH7HA represents a promising influenza vaccine platform for further development.
Keywords: Adjuvant; Advax; Delta inulin; H7N9; Influenza; Pandemic; Vaccine.